Tenofovir: new indication. In chronic hepatitis B: beware bone toxicity.
Tenofovir is more effective than adefovir in reducing viraemia in the short term, but with no histological or serological evidence of improvement. It is also associated with a small increase in gastrointestinal disturbances and exacerbation of hepatitis. Its renal and bone risks also need to be closely monitored.